CD47 and neoplasm: Given that myeloid cells are prominent in tumor microenvironment and that CD47 expression correlated with worse outcome, lower response to therapy and an immunosuppressive tumor microenvironment, it was of interest to assess the anti-tumor efficacy of anti-CD47 therapy alone and in combination especially with PARP inhibition or antibody drug conjugates.